Adoptive cellular immunotherapy for the treatment of malignant gliomas (Q40601126)

21 September 2017

title

Adoptive cellular immunotherapy for the treatment of malignant gliomas (English)

1 reference

21 September 2017

1 reference

3

M Odaimi

0 references

author name string

R L Hayes

1

1 reference

21 September 2017

E Arbit

2

1 reference

21 September 2017

S Pannullo

4

1 reference

21 September 2017

R Scheff

5

1 reference

21 September 2017

D Kravchinskiy

6

1 reference

21 September 2017

C Zaroulis

7

1 reference

21 September 2017

language of work or name

1 reference

1 July 2001

1 reference

Critical Reviews in Oncology Hematology

21 September 2017

published in

1 reference

21 September 2017

volume

39

1 reference

21 September 2017

issue

1-2

1 reference

21 September 2017

page(s)

31-42

1 reference

21 September 2017

cites work

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Reoperation for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Reoperation in the treatment of recurrent intracranial malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Survival and functional status after resection of recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Cytolytic effects of autologous lymphokine-activated killer cells on organotypic multicellular spheroids of gliomas in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

An improved method for the generation of human lymphokine activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

High activity iodine-125 interstitial implant for gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

The eosinophil-mediated antitumor activity of interleukin-4.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Tumour-associated eosinophilia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Tumor-associated eosinophilotactic factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

Morphologic evidence suggestive of host-tumor cell interactions in vivo in human cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900122-6

7 January 2021

10.1016/S1040-8428(01)00122-6

Identifiers

DOI

1 reference

21 September 2017

1 reference